In the September 18 issue of the Archives, Arzt and colleagues1 showed that patients with systolic heart failure (HF) only sleep approximately 5 hours per night vs 6.5 hours in a community sample. The authors suggest that the reduced sleep duration in HF could be caused by elevated central noradrenergic activity stimulating alertness. This suggests that pathophysiological factors leading to HF, or the presence of HF itself, may cause shortened sleep. In such a case, optimal therapy for HF may improve sleep, and untreated HF may result in even shorter sleep. Indeed, the accepted approach to the treatment of secondary insomnia is to treat the underlying medical disorder, assuming that the sleep will thereby improve. It would be worthwhile to test this assumption and determine whether sleep improves in a group of patients with HF after instigating therapy. On the other hand, instead of pathophysiological factors related to HF causing shortened sleep, we wonder whether the short sleep in HF is an adverse effect of medication use, since this population was optimally treated.2 For example, in the study by Arzt et al,1 72% of the patients with HF used diuretics that can cause nocturnal polyuria. Thus, adjusting the timing of diuretic use possibly could improve sleep. Furthermore, 81% of their patients with HFused β-blockers, and β1-adrenergic receptor blockers are known to suppress nocturnal plasma melatonin,3 which can result in reduced sleep.4 This hypothesis, that β1-blockers reduce sleep in patients with HF via melatonin suppression, raises the potential for nighttime melatonin supplementation as a therapy to counter an adverse effect of β-blockers and restore normal sleep in this population. Finally, it is established that acute partial sleep loss leads to increased sympathetic activity.5 The authors suggest therefore that sleep loss itself could contribute to the development of HF via its effects on the cardiovascular system.1 Clearly, further studies are needed, but if sleep loss does contribute to the development of HF, then optimizing HF therapy while counteracting any adverse effects of HF medications on sleep duration conceivably could have 2 advantages: improved sleep and improved HF outcome.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
How Should We Treat Patients With Heart Failure? A Problem in Interpreting Study Results
Figure 17.1-1. Distribution of Brain Natriuretic Peptide Values Among Patients With and Without...
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.